Caution: Big Pharma's tax-avoidance tactics are in jeopardy. As Bloomberg reports, U.S. lawmakers are eyeing overseas profits--and the $7 billion-plus in taxes sidestepped by drugmakers last year--with changes in mind.
The rule for how drug and device makers will have to disclose their financial ties to doctors is 15 months overdue and the longer White House officials sit on it, the more lobbying it gets from different sides trying to shape its final wording.
About 6 months after the FDA gave the nod to Vertex Pharmaceuticals' pricey drug Kalydeco, the European Commission also approved the treatment for patients with cystic fibrosis that have a certain genetic mutation.
Sen. Charles Grassey, a longtime FDA critic, isn't pulling any punches now that the agency spying on employees has been detailed in the press.
In a blistering letter to the FDA, Sen. Charles E. Grassley said that the electronic surveillance of the scientists inside the agency was approved by its attorneys in writing. And he's not in the least bit happy to see headlines about secret probes aimed at the agency's internal critics.
The Senate Finance Committee launched an investigation yesterday into the ties among companies that sell pain drugs, pain experts, patient advocacy groups and professional organizations, The New York Times reports.
Two doctors who've previously drawn scrutiny for failing to disclose financial ties to the drug industry are now under fire for publishing a treatment text that may have been ghostwritten by
The FDA's Office of Criminal Investigation is now joined in the congressional spotlight by the Government Accountability Office, which had been sent to investigate it. The case provides a rare
There's been a move afoot for some time to separate the FDA's drug-safety operations from the Center for Drug Evaluation and Research, which now oversees both drug approvals and safety. The thinking
Drugmakers could well be rejoicing at the news that Paul Thacker, an investigator for Sen. Chuck Grassley (R-Iowa) who led some high-profile pharma probes, is leaving to join a non-profit group.